Crescent Biopharma (NASDAQ:CBIO) reported quarterly losses of $(0.70) per share which beat the analyst consensus estimate of $(0.98) by 28.57 percent. This is a 96.43 percent increase over losses of $(19.63) per share from the same period last year. The company reported quarterly sales of $1.039 million which beat the analyst consensus estimate of $357.143 thousand by 190.92 percent.